Chronic Rhinosinusitis With Nasal Polyps, Glucocorticoids
Conditions
Brief summary
Topical and systemic steroids constitute the first choice in medical treatment for nasal polyps. Glucocorticoids sensitivity is significantly correlated with CST1 level in nasal secretions. The goal of this single-arm clinical trial based on a multicenter platform is to test CST1 in patients with chronic rhinosinusitis and nasal polyps before and after oral glucocorticoid therapy. Endoscopic polyp score, Total Nasal Symptom Score(TNSS), SNOT-22 score and other biomarkers are also evaluated before and after the treatment. Researchers will develop a CST1 predictive model of oral glucocorticoid therapy for Chronic Rhinosinusitis with Polyps.
Interventions
Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
Sponsors
Beijing Tongren Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. All meet the diagnostic criteria of CRSwNP in EPOS2020 (Age 18-70 years old); 2. Investigator-assessed endoscopic bilateral Nasal Polyp Size Score (NPSS) was greater than or equal to 4 (minimum score of 2 per nasal cavity);
Exclusion criteria
1. Oral glucocorticoid contraindications, such as diabetes, femoral head necrosis, gastric ulcer, etc. 2. Medication history of oral glucocorticoids or immunomodulator within 1 months before enrollment, antibiotics within 2 weeks; 3. fungal sinusitis, allergic fungal sinusitis (AFRS), cystic fibrosis, primary ciliary dyskinesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in endoscopic polyp score | Baseline, week 4, week 6 | Bilateral polyp volume size described using the Nasal Polyp Size Score (NPSS) score. (0 - 4 points per side: 0 = no polyp; 1 = small polyp in the middle meatus, not reaching the inferior border of the middle turbinate; 2 = small polyp in the middle meatus, reaching the inferior border of the middle turbinate; 3 = large polyp protruding from the middle meatus, not reaching the inferior border of the inferior turbinate; 4 = large polyp that almost causes most or complete obstruction of the nasal cavity.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of serum cortisol | Baseline, week 4, week 6 | The change of serum cortisol level |
| The change in Total Nasal Symptom Score | Baseline, week 4, week 6 | Total Nasal Symptom Score was are graded on a 3-point scale. (0= no symptoms; 1= mild symptoms; 2= moderate symptoms; 3= severe symptoms). |
| The change in SNOT-22 score | Baseline, week 4, week 6 | The 22-item Sino-nasal outcome test (SNOT-22) was used to evaluate the changes in symptoms of patients. According to the severity of symptoms caused by RCRS, each item was divided into 6 levels: no distress (0 points), mild distress (1 point), mild distress (2 points) ), moderate distress (3 points), severe distress (4 points), very severe distress (5 points). The higher the score, the more severe the symptoms, and the final total score of the item is counted. |
| The change in asthma ACQ Score | Baseline, week 4, week 6 | For patients with asthma, we assessed the change of asthma symptoms through the Asthma Control Questionnaire(ACQ). Each question was scored on a scale of 0 to 6 according to the severity. The result score of each item was averaged. A score of \<0.75 indicated that the asthma had been completely controlled; a score of 0.75-1.5 indicates well-controlled asthma; a score of \>1.5 indicates that asthma is not controlled. |
| The change of CST1 | Baseline, week 4, week 6 | The change of Cystatin 1 |
| The change of biomarker | Baseline, week 4, week 6 | Changes in expression levels of biomarker in nasal brush exfoliated cells, nasal secretions and nasal microbes. |
| The change in AE / SAE recording | Baseline, week 4, week 6 | Any adverse event |
| The change of inflammatory cell | week 4, week 6 | The change of inflammatory cell in nasal polyps |
Countries
China
Contacts
Primary ContactLou Zhang
Outcome results
None listed